Three-drug combo targets immune suppression to overcome melanoma resistance
Medical Xpress
February 27, 2026
For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment options remain frustratingly limited. A new study from Vanderbilt researchers led by Professor Emerita of Pharmacology Ann Richmond outlines a promising therapeutic strategy that may resensitize these resistant tumors to immunotherapy.
Verticals
healthmedical
Originally published on Medical Xpress on 2/27/2026